Repligen Co. (NASDAQ:RGEN) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio trimmed its position in Repligen Co. (NASDAQ:RGEN) by 4.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,357 shares of the biotechnology company’s stock after selling 992 shares during the period. Public Employees Retirement System of Ohio’s holdings in Repligen were worth $3,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new stake in Repligen during the 3rd quarter valued at approximately $658,000. MML Investors Services LLC lifted its position in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after purchasing an additional 89 shares during the period. Kensington Investment Counsel LLC grew its position in Repligen by 1.9% during the 3rd quarter. Kensington Investment Counsel LLC now owns 10,041 shares of the biotechnology company’s stock worth $1,494,000 after purchasing an additional 184 shares during the period. iSAM Funds UK Ltd purchased a new position in shares of Repligen during the 3rd quarter valued at about $203,000. Finally, DF Dent & Co. Inc. lifted its holdings in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the topic of several analyst reports. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Wells Fargo & Company assumed coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Finally, Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Up 2.9 %

RGEN stock opened at $160.92 on Tuesday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a 50-day simple moving average of $142.66 and a 200-day simple moving average of $141.59. The stock has a market capitalization of $9.02 billion, a P/E ratio of -434.92, a P/E/G ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 earnings per share. Equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.